Bevacizumab biosimilar (Alphamab/R-Pharm)

贝伐珠单抗生物类似药 (Alphamab/R-Pharm)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBevacizumab biosimilar (Alphamab/R-Pharm)
Drug Alias Name贝伐人源化单抗生物仿制药 (Alphamab/R-Pharm)贝伐单抗生物仿制药 (Alphamab/R-Pharm)贝伐珠单抗生物仿制药 (Alphamab/R-Pharm)RPH-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian FederationMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSuzhou Alphamab Co LtdR-Pharm Jsc
China Registration ClassN/A

Develop Information

Active CompaniesR-Pharm JscSuzhou Alphamab Co Ltd
Inactive CompaniesTrpharm
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A